Sheila DeWitt, PhD, has been named vice president of business development and strategic planning for EPIX Pharmaceuticals (Cambridge, Massachusetts). DeWitt most recently worked as a consultant to the biotech industry, including EPIX, leading the evaluation of strategic business initiatives. Prior to consulting, she was vice president of portfolio development at ArQule. EPIX develops imaging pharmaceuticals for the diagnosis, treatment and monitoring of disease.

Steve Peltzman has been named CEO of Saliva Diagnostics Systems (New York). He has been working closely with the company as a consultant for the last six months. Peltzman has more than 30 years of experience in technology-based healthcare companies, including helping start Applied BioTechnology, where he served as president. That company was later sold OSI Pharmaceuticals, where Peltzman became chief operating officer of the consolidated entity and later president and COO. Saliva Diagnostic Systems manufactures a rapid point-of-care testing device for infectious diseases, as well as oral fluid specimen collection devices using a volume adequacy indicator for drugs-of-abuse testing and other clinical uses.

John Kuo has been promoted by Varian Medical Systems (Palo Alto, California) to serve as corporate vice president and general counsel, effective July 2. Kuo, currently Varian's corporate secretary and associate general counsel, is replacing Joseph Phair, corporate vice president and general counsel, who will retire after 26 years with the company. Varian Medical Systems is a manufacturer of integrated cancer therapy systems and a supplier of X-ray tubes and flat-panel digital subsystems.